Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY23 results · Apr–Jun 2022
Aarti Drugs reported revenue from operations of ₹621.96 crore (up 7.2% from Q1 FY22) and net profit of ₹34.78 crore (down 28.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 621.96 | 579.95 | +7.2% | 694.27 | −10.4% |
| Other income | 0.26 | 1.62 | −84.0% | 2.96 | −91.2% |
| Total income | 622.22 | 581.57 | +7.0% | 697.23 | −10.8% |
| Profit before tax | 48.03 | 64.68 | −25.7% | 70.50 | −31.9% |
| Net profit for the period | 34.78 | 48.81 | −28.7% | 55.32 | −37.1% |
| Attributable to shareholders of the company | 34.79 | 48.81 | −28.7% | 55.34 | −37.1% |
| EPS, basic (₹) | 3.76 | 5.25 | −28.4% | 5.97 | −37.0% |
| Net margin (%) | 5.6 | 8.4 | 8.0 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 551.20 | 505.79 | +9.0% | 641.48 | −14.1% |
| Other income | 0.24 | 1.64 | −85.4% | 0.62 | −61.3% |
| Total income | 551.44 | 507.43 | +8.7% | 642.10 | −14.1% |
| Profit before tax | 36.35 | 60.04 | −39.5% | 67.00 | −45.7% |
| Net profit for the period | 26.35 | 45.54 | −42.1% | 53.00 | −50.3% |
| EPS, basic (₹) | 2.85 | 4.90 | −41.8% | 5.72 | −50.2% |
| Net margin (%) | 4.8 | 9.0 | 8.3 |
Consolidated
- Filed with BSE
- 28 Jul 2022, 15:43 IST
- Board meeting
- 27 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2022, 15:43 IST
- Board meeting
- 27 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Audited
- Source
- XBRL filing on BSE